Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
Location: United States, California, Brisbane
Employees: 201-500
Phone: +1 650-614-5220
Total raised: $145M
Founded date: 2011
Investors 6
| Date | Name | Website |
| - | SWK Holdin... | swkhold.co... |
| - | Aisling Ca... | aislingcap... |
| - | Foresite C... | foresiteca... |
| - | RA Capital... | racap.com |
| - | Vivo Capit... | vivocapita... |
| - | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.11.2016 | - | $145M | - |
Mentions in press and media 18
| Date | Title | Description |
| 06.06.2024 | Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 | Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J., June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of ... |
| 03.03.2022 | Egg allergy trials halted by Aimmune; Atlas closes its 13th fund for $450M | A Phase II trial for Aimmune’s drug to treat children and young adults with egg allergies has been terminated. “The study was prematurely terminated by the Sponsor based on difficulties in meeting enrollment goals, especially during the COV... |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know: – Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies. – LVP4 will invest opportunistica... |
| 23.09.2020 | Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies | - Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - - In 2020 to date, Longitude portfolio companies announced 4 IP... |
| 31.08.2020 | Aimmune Therapeutics soars 172% after Nestle agrees to acquire the peanut allergy treatment company for $2.6 billion | Aimmune Therapeutics soared 172% on Monday after Nestle Health Science agreed to acquire the company for $34.50 per share, or $2.6 billion. Aimmune developed a treatment for peanut allergies, Palforzia, which was approved by the FDA in Janu... |
| 05.02.2020 | Nestlé puts $200M more behind a treatment for peanut allergy | Aimmune’s patients won’t ever be able to eat much or even most of their candy, but every time they open a capsule, they’ll be consuming a product Nestlé helped produce. Since the immunotherapy company completed its Phase II s... |
| 13.09.2019 | FDA expert panel gives thumbs-up to Aimmune’s peanut allergy drug | A panel of experts convened by the Food and Drug Administration voted in support of the agency approving a drug to treat patients with peanut allergy. The FDA’s Allergenic Products Advisory Committee voted 7-2 Friday that available efficacy... |
| 20.06.2019 | Assessing the value of new food allergy treatments must include quality of life | Walk into any classroom in America today and you’ll likely find at least two children with a food allergy. More than 40% of such children have experienced a serious allergic reaction such as anaphylaxis, a severe, potentially life-threateni... |
| 12.11.2018 | Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies | Nestlé Health Science is upping its bet on Aimmune Therapeutics by $98 million $AIMT, with its now $276 million stake in the company giving it 19% of the biotech’s equity. Allied on Aimmune’s peanut allergy med, Nestlé is b... |
| 05.05.2018 | A life sciences firm run by a top VC and a cofounder of Alphabet’s life sciences arm, just raised its biggest fund yet | There’s no end to the number of fascinating devices and therapies being created right now in the fields of health and life sciences. The investors behind them are often pretty interesting, too, given the expertise needed to make informed be... |
Show more